Esperion Therapeutics, Inc.
Bempedoic acid pregnancy surveillance program
A surveillance study of females exposed to bempedoic acid or bempedoic acid/ezetimibe fixed combination drug product (FCDP) during pregnancy. Observational outcome data will be collected on pregnant females through pregnancy and infants through the first year of life.
Inclusion Criteria: Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \[LMP\] to pregnancy outcome Exclusion Criteria:
Bempedoic Acid 180 MG
Bempedoic Acid 180 MG / Ezetimibe 10 MG
Verify or correct the compensation shown for this listing.